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I 
T is just 10 years since the peptide, transforming growth 
factor-/31  (TGF-~I) 1,  was isolated from human plate- 
lets, human placenta,  and bovine kidney and charac- 
terized as a discrete molecular entity, namely a 25-kD homo- 
dimer  with  a  unique  NH2-terminal  sequence.  Two  years 
later this molecule was cloned, and subsequently four other 
closely related isoforms have been found in vertebrates; three 
isoforms (TGF-~s 1, 2, and 3) are known in man. TGF-~ can 
now be considered the prototype of a multifunctional  cyto- 
kine, especially after the discovery that it could act both as 
an inhibitor and stimulator of  cell replication,  as well as con- 
trol the synthesis of many of the components of the extracel- 
lular matrix (for reviews of the above see Roberts and Sporn, 
1990; Massagu6,  1990; Moses et al., 1990; Sporn and Rob- 
erts, 1990). There has been immense progress in TGF-/~ re- 
search in the past two years. This mini-review will highlight 
some of these accomplishraents and indicate a few challenges 
for the future. We will confine this brief review to the TGF-/3s 
themselves and will not consider the extended TGF-B family, 
which includes the inhibins,  activins,  bone morphogenetic 
proteins, and related morphogenetic peptides,  all of which 
are of increasing  importance in many areas of cell biology, 
such as reproduction and development. 
Molecular Structure of TGF-I~ 
The molecular structure of the TGF-fl2 dimer has been de- 
termined at high resolution by x-ray crystallography (Daopin 
et al., 1992; Schlunegger and Griitter,  1992). Several unique 
features have emerged from these studies:  the dimer has an 
extended,  rather  than  a  compact,  globular conformation; 
eight of the nine cysteine residues in each monomer chain 
are involved in an unusual,  compact pattern of intrachain 
disulfide bridges, called a "TGF-~ knot";  and there is only 
a single  interchain  disulfide  bridge, suggesting that hydro- 
phobic interactions  between the two chains are of major im- 
portance in stabilizing the dimer. Furthermore, there are two 
cavities, accessible to water, between the interchain disulfide 
bridge and the hydrophobic  cores in the interface area, al- 
though the functional  implications  of this unusual  hydro- 
philic area in the interior of the molecule are not clear at 
present.  The possibility that  the interchain  disulfide  bond 
might undergo reversible reduction and reoxidation,  as has 
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transforming growth factor-~. 
been shown for a disulfide bond in the transcription  factors, 
Fos and Jun (Abate et al., 1990), remains to be determined. 
In addition to the above studies  performed on crystalline 
TGF-ff2,  NMR analysis of TGF-~I  in solution (Archer et 
al.,  1993) has confirmed many aspects of the above x-ray 
analysis.  Moreover,  the NMR studies  suggest that in solu- 
tion TGF-/3 may exist in several conformations.  The three- 
dimensional  analysis  from  these  molecular  studies  will 
provide a firm basis for future understanding  of many as- 
pects of TGF-/~ function, such as its interaction  with spe- 
cific receptors,  or the biological specificity  of particular 
isoforms. 
Receptors and Other  Binding Proteins  for TGF-~ 
The molecular cloning of a TGF-/3 receptor which appears 
to function in signal  transduction has only been achieved 
within the past year. Although at least nine different proteins 
have been reported to bind TGF-/~ specifically, only two ma- 
jor species (receptors I and ]I) are believed to be signalling 
molecules (for a review see Massagn6,  1992);  the type H 
receptor has been cloned (Lin et al., 1992) and shown to be 
a member of a new serine/threonine  kinase receptor family, 
which also includes two homologous activin receptors. The 
details of  the signal transduction pathway remain to be estab- 
lished,  although  it appears that  cooperativity between the 
type I and type II receptors is involved in binding  of the 
ligand  and  the  initiation  of signalling  (Massagn6,  1992; 
Wrana  et al.,  1992). 
"Receptor" Ill (also known as betaglycan) and the related 
molecule, endogiin,  bind TGF-fl with high affinity, but have 
yet to be shown to be directly involved in signal transduction 
(Lopez-Casillas et al.,  1991; Wang et ai.,  1991; Cheifetz et 
al.,  1992); it has been suggested that they control the avail- 
ability of TGF-fl in the local extracellular  microenvironment 
and thus may control the presentation of active TGF-/~ to the 
signalling receptor complex. Interestingly,  endoglin,  which 
is found in relatively high concentrations in endothelial cells, 
binds TGF-~I  and -f13 with high affinity, but does not bind 
TGF-/32 (Cheifetz et al., 1992); this specificity of binding of 
TGF-/~ isoforms correlates with the biological responsive- 
ness of  endothelial cells to the three isoforms (highly respon- 
sive to TGF-/~I and 4/3, much less so to TGF-ff2). The eluci- 
dation of the specificity of binding and action of the various 
isoforms in endothelial  cells will be facilitated by the recent 
synthesis of chimeric TGF-betas which structurally are pre- 
dominantly TGF-/~2, but contain certain amino acid replace- 
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cules act like TGF-B1 on endothelium (Qian et al.,  1992). 
As described below,  the cardioprotective action of TGF-/3 
may depend largely on its action on endothelium; thus the 
problem of isoform specificity in this tissue may be of clini- 
cal importance. 
Cellular Actions of TGF-fl 
In light of its multifunctional nature, it is not surprising 
that study of TGF-/3 is germane to almost every cell in the 
body. Several recent reviews have emphasized the role of 
TGF-/3 in control of the cell cycle, and in particular the inter- 
face between TGF-/3 and suppressor genes such as Rb. (Moses 
et al., 1990). Although in some instances the ability of TGF-/3 
to suppress epithelial proliferation is coupled to the func- 
tional integrity of the RB protein and its ability, in turn, to 
suppress  the  function of the myc gene (Pietenpol et al., 
1991), there are many instances in which this model does not 
hold (Roberts et al., 1991). Thus, the question of the mecha- 
nisms whereby epithelial cells lose their sensitivity to the 
regulatory actions of TGF-/3 during the process of carcino- 
genesis remains of paramount importance. Comparison of 
human colon carcinoma cell lines of high and low degrees 
of malignancy has shown a loss of responsiveness to TGF-/3 
as carcinogenesis progresses (Manning et al.,  1991), while 
the expression of  anti-sense RNA to TGF-/3 can convert a co- 
lon carcinoma line of low malignancy to  a  more  highly 
malignant one (Wu et al.,  1992). 
A related phenomenon is the ability of TGF-fl to suppress 
the appearance of the transformed phenotype in co-cultures 
of ms-transformed keratinocytes and normal dermal fibro- 
blasts; in this case, expression of TGF-~3 by a mesenchymal 
cell modulates the malignant phenotype in a neighboring ep- 
ithelial cell (Missero et al., 1991). These data are of obvious 
relevance to the entire issue of mesenchymal-epithelial in- 
teractions, both in normal development as well as in carcino- 
genesis. In epithelial carcinogenesis, it has generally been 
assumed that epithelial cells "invade" the underlying mesen- 
chymal stroma, and that the stroma is a relatively passive 
partner in this interaction. A newer perspective would add 
the possibility that mesenchymal cells might actively sup- 
press carcinogenesis in adjacent epithelia, and that the loss 
of such active suppression by mesenchyme might contribute 
to carcinogenesis. If this is indeed the case, then it will be 
necessary to study the role of tumor suppressor genes in the 
mesenchyme, as well as in the epithelium, of any tissue dur- 
ing carcinogenesis. 
As has been noted before, tissues, as well as individual 
cells, need to be regarded as the targets for cytokine action 
(Nathan and Sporn, 1991), and the function of TGF-fl as an 
information channel between cells provides an excellent ex- 
ample of this paradigm. We would suggest that the role of 
TGF-fl in regulating mesenchymal-epithelial interactions, as 
is already known from embryologic studies (Symposium, 
1992),  will become a central theme in the cell biology of 
many tissues of the adult animal. The recent demonstration 
that the steroid analogue, tamoxifen (a useful agent for adju- 
vant therapy of breast cancer), can induce the formation of 
TGF-fl in the stroma of human breast tumors provides an ex- 
cellent example of the practical importance of this topic 
(Butta et al.,  1992). 
The role of TGF-/3 in mediating the response of both cells 
and tissues to injury is another area of intensive investiga- 
tion, with particular relevance to the problem of protecting 
the heart and brain from damage caused by anoxia or reper- 
fusion. TGF-B has an intrinsic role in the physiology of iso- 
lated cardiac myocytes, as shown by its ability to maintain 
the rhythmic beating of these cells in culture and to protect 
them from the deleterious action of interleukin-1  (Roberts et 
al., 1992a).  This appears to be mediated by the suppressive 
action of TGF-fl on the synthesis of nitric oxide induced by 
IL-1 (Roberts et al., 1992b).  Other cardioprotective actions 
are mediated by the ability of TGF-/3 to prevent the adhesive- 
ness of neutrophils to endothelium; this is a first and critical 
step in reperfusion injury caused by neutrophils. In isolated 
human fibroblasts, hypoxia upregulates synthesis of TGF-B1 
(Falanga et al., 1991); this has not yet been shown in isolated 
myocytes. It will be important to determine the mechanism 
whereby low oxygen tension activates the synthesis of TGF-/3. 
The brain is a new organ for studying the role of TGF-/3 
in modifying the response of cells to injury. Recent studies 
have shown that TGF-/3 stimulates the synthesis of nerve 
growth factor (NGF) in cultured astrocytes and in neonatal 
brain in vivo,  and further, that mRNA for TGF-B1 is in- 
creased in cerebral cortex after a penetrating brain injury 
(Lindholm et al., 1992). Additionally, in cell culture experi- 
ments, TGF-BI, but not TGF-B2, protected isolated neurons 
from degeneration and death induced by hypoxia or excess 
glutamate (Prehn et al., 1993). In co-cultures of  neurons and 
non-neuronal cells from dorsal root ganglia, TGF-fl markedly 
increased neuronal survival, particularly when non-neuronal 
cells were present (Chalazonitis et al.,  1992);  these neuro- 
trophic actions are believed to depend on mediation by mole- 
cules immunologically  related to NGE Clearly, further stud- 
ies will be required to define the neuroprotective actions of 
TGF-/3 and to determine if it might have a  useful neuro- 
trophic action in vivo, either directly or by its ability to in- 
duce other neurotrophic cytokines such as NGF. Whether 
TGF-fl mediates any trophic action of glial cells upon neu- 
rons under normal physiological conditions remains to be 
determined. With the intense current interest in the role of 
cytokines in the pathogenesis and treatment of many de- 
generative diseases of the nervous system, it will be of criti- 
cal importance to define the role of TGF-fl in any neuronal- 
glial cytokine network. 
Thus, with respect to the generic problem of injury to both 
cells and tissues, as well as its repair, data from many studies 
indicate that TGF-B exerts a homeostatic action, either by 
lessening the extent of injury or increasing repair itself. In- 
jury and repair are clearly coupled to each other at both the 
cell and tissue level; we would suggest that TGF-/3 is a criti- 
cal molecule for transmission of  the information that enables 
cells and tissues to make appropriate responses to injury. 
Physiologic and Therapeutic Roles 
Striking advances have occurred in studies conducted with 
intact animals. The technique of homologous recombination 
has created mice with a  non-functional gene for TGF-BI 
CKulkarni et al., 1993; Shull et al., 1992). These "knockout" 
mice are born without any apparent gross developmental de- 
fect; however,  within two to three weeks they develop a 
diffuse inflammatory syndrome, characterized by massive 
infiltrates of mononuclear cells in vital organs such as the 
heart and lungs, leading uniformly to death. These animals 
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in inflammation and immunity, with a host of applications in 
many human diseases, particularly those of an autoimmune 
nature. The creation of mice that over-express TGF-/3 has 
also been achieved, although many attempts to make such 
transgenic mice have led to embryonic lethality. With restric- 
tion of expression of TGF-/~ to the mammary gland, using 
various promoters, one can obtain mice with defective devel- 
opment of mammary ducts and glandular end-buds, or with 
impaired ability to lactate (D. Pierce and H. Moses, personal 
communication; G. Merlino, C. Jhappan, and G. Smith, per- 
sonal communication). 
Potential therapeutic applications for TGF-fl have been ex- 
plored in many laboratories (reviewed in Roberts and Sporn, 
1992a),  with the repair of injury a  fundamental theme in 
many tissues. The anoxic, ischemic, and infarcted heart or 
brain  all may be  regarded as  unique wounds of varying 
degrees of severity; thus, data obtained from studies of the 
role of  TGF-/~ in more conventional aspects of  wound healing 
will be useful in these newer areas. In the infarcted heart 
there is a strong induction oftbe 1.9-kb transcript of TGF-fll, 
which is believed to have an important role in the response 
to injury (Qian et al., 1991). The possibility of using exoge- 
nous TGF-/3 to protect the heart from reperfusion injury, pre- 
viously demonstrated in the rat (Lefer, 1991), has received 
further support from studies in the cat, in which TGF-~ ex- 
erts a potent effect on endothelium, antagonizing the effects 
of both IL-1 and TNF-o~ on emigration of neutrophils from 
the vascular compartment (Lefer et al., 1993). With respect 
to cerebrovascular injury, there has been the first report of 
the ability of TGF-fl to protect the brain from ischemic cell 
death in vivo;  these  studies have used a  rabbit model of 
thrombotic stroke (C.  Gross, personal communication). 
The potential for using TGF-fl for surgical wound healing 
has been increased by the demonstration that a single dose 
of  TGF-/~, administered  systemically  to  animals  before 
wounding,  enhances  subsequent healing  (Amento et  al., 
1991).  The mechanism of this phenomenon is not under- 
stood, but may involve a priming of  macrophages so that they 
respond more effectively  at the wound site. In repair of bone, 
major advances have also occurred; a single topical adminis- 
tration of less than a microgram of TGF-fl can cause com- 
plete closure of a skull defect that otherwise would not heal 
(Beck et al., 1991). The ability of TGF-fl to have such a pro- 
found and prolonged effect on bone healing is undoubtedly 
a reflection of its potent mitogenic effect on osteoblasts, as 
well as its known capacity for auto-induction. 
The full clinical potential for use of TGF-~ to prevent tis- 
sue injury and enhance repair is yet to be realized. However, 
the first definitive clinical report has appeared with the publi- 
cation of the successful use of TGF-fl2 to treat holes in the 
macular portion of the retina; these holes represent localized 
areas of retinal detachment and result in severe loss of vi- 
sion. In a large series of patients with macular holes, direct 
application of TGF-fl to the macula caused a significant im- 
provement in vision (Glaser et al., 1992). TGF-fl is believed 
to induce microscopic fibrosis at the edge of macular holes, 
thereby preventing further retinal detachment. This study is 
the first report of the use of a cytokine to alter the outcome 
of a retinal disease in man. Since retinal epithelium is of neu- 
ral origin, it also opens the possibility for further evaluation 
of any potential neurotrophic action of TGF-fl, whether it be 
in the retina for a condition such as diffuse degeneration of 
macular photoreceptors, or in the brain itself. Conceivably, 
such activity might be mediated by glial cells, such as the 
Miiller cells of the retina, which correspond to the radial 
glial cells of the central nervous system (both Miiller cells 
and radial glial cells are known to stain intensely for TGF-/~) 
(Unsicker et al.,  1991; Flanders et al.,  1991). 
While there are many instances in which TGF-fl may en- 
hance a beneficial healing response, there are clearly situa- 
tions in which persistent over-expression or dysregulated ac- 
tivation of TGF-fl elicits an over-response which may lead to 
serious fibrotic or proliferative disease, such as glomerulo- 
nephritis or pulmonary fibrosis. In a similar manner, TGF-/~ 
may enhance the desmoplastic response to malignant cells 
and  potentiate  their  metastatic  capacity.  The  topic  of 
maladaptive responses to TGF-/~ and their role in disease has 
been reviewed recently (Border and Ruoslahti,  1992)  and 
will not be considered further here. 
New Challenges 
The impact of TGF-/3 research on cell biology, physiology, 
pathology, and clinical medicine has created a  new set of 
problems and challenges, ranging from basic scientific to ap- 
plied clinical considerations. We will mention only a few. At 
the molecular level, structure and function must be rational- 
ized in the most basic terms. What is the molecular fit be- 
tween the various isoforms and the various receptor and 
binding molecules? How is the signal first transduced from 
ligand to receptor, and then what are the intracellular targets 
for the kinase activity of the receptor? What is the role of 
TGF-fl in the regulation of intracellular calcium homeosta- 
sis,  as  shown by the  recent cloning of a  new  ryanodine 
receptor-calcium channel that is regulated by TGF-/3 (Gian- 
nini et al., 1992)? What are the molecular pathways whereby 
TGF-/3 participates in the regulation of the cell cycle, espe- 
cially the suppression of DNA synthesis in epithelial cells? 
The advances of the past year now open these problems to 
more direct experimentation. 
Is there an entire domain of intracellular physiology medi- 
ated by TGF-fl, independent of  the known cell-surface recep- 
tors (Sporn and Roberts, 1990)? The presence of significant 
amounts of TGF-/~ localized in mitochondria of cardiac myo- 
cytes and hepatocytes (Heine et al., 1991) strongly suggests 
that this may be the case. Although we speak of each of the 
three mammalian isoforms as single, discrete structures, can 
they in turn be modified by post-translational mechanisms 
(such as acylation, alkylation, phosphorylation, or prenyla- 
tion),  thus  adding  to  the  informational  content  of  the 
cytokine networks in which TGF-/3 participates? Since aber- 
rant expression of TGF-/~ may be pathogenic (Border and 
Ruoslahti,  1992),  can  new  antagonists,  such  as  soluble 
receptors or other peptides with high binding affinity, be de- 
veloped  for  treatment?  Conversely,  can  the  potent  im- 
munosuppressive activity of TGF-/$ be used in a practical 
manner for control of autoimmune disease, without incur- 
ring undesirable side effects (Johns et al., 1991; Kuruvilla et 
al., 1991; Miller et al., 1992; Racke et al., 1991)? Is it better 
to use agents such as retinoids, vitamin D analogues, and 
other ligands of the steroid-receptor superfamily to induce 
TGF-/~, rather than to use TGF-fl itself as a therapeutic agent 
(Roberts and Sporn, 1992b)? What is the tissue-specific and 
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agents? It is already known that they can induce the expres- 
sion and activation  of latent TGF-fl. What are the overall 
mechanisms for control of the activation of latent TGF-B by 
proteolytic  enzymes,  and how are  the activities  of other 
cytokines, such as TNF, gamma-interferon,  and basic FGF, 
in turn regulated  by active  TGF-B in a homeostatic loop 
(Flaumenhaft  et al.,  1992)? 
The control of synthesis of TGF-B, particularly by steroids 
and related  molecules,  is often at the posttranscriptional 
level; what are the mechanisms, and how are the unusually 
long 5'- and 3'-untranslated regions of the genes for TGF-B 
1, 2, and 3 involved in the regulation of the synthesis of the 
respective peptides (Kim et al.,  1992)? How much function 
is regulated transcriptionally, posttranscriptionally, or by al- 
teration of latency? How can the new mice in which the TGF- 
fll gene has been inactivated best be used to study selective 
aspects  of TGF-fl function, including the respective  func- 
tions of each of the three isoforms? Can tissue-specific gene 
replacement  therapy be designed that would allow study of 
the physiology and pathology of TGF-B in specific organs of 
mice with the null genotype? 
The role of TGF-B in mediating homeostatic responses to 
cell and tissue injury will undoubtedly receive much more 
attention, particularly in view of the potential of using TGF-B 
for therapeutic  purposes. Although some homeostatic ac- 
tions of TGF-fl can be analyzed  at the single cell level, we 
would suggest that the study of the role of TGF-B in mediat- 
ing cooperative interactions between pairs of cells will be of 
increasing importance. As examples, one may cite the inter- 
actions between pericytes  and capillary  endothelial  cells, 
glia and neurons, satellite cells and skeletal muscle cells, or 
myoepithelial  cells and mammary epithelial  cells.  In some 
of these pairs, TGF-B has already been shown to be a critical 
regulator of tissue response.  One might consider this to be 
a local tissue decision network, with 'rGF-B acting as a medi- 
ator to couple the appropriate response of a pair of cells to 
their environment. 
The above is only a partial list of the many challenges that 
lie ahead in TGF-fl research. The past two years have yielded 
an  abundance  of important  information  and  new  leads, 
which now make these challenges  much more accessible for 
investigation at the laboratory bench or in the clinic.  Studies 
of the cell biology of TGF-fi will continue to be a key compo- 
nent in linking basic molecular studies with clinical applica- 
tions. 
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